Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
X-linked intellectual disability-seizures-psoriasis syndrome has been described in four male cousins. The mode of inheritance is thought to be X-linked recessive.
Biomarker and diagnostic research for X-linked intellectual disability-seizures-psoriasis syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for X-linked intellectual disability-seizures-psoriasis syndrome.
304 publications have been identified in PubMed for X-linked intellectual disability-seizures-psoriasis syndrome. Kisho has analyzed 140 by research type. Research spans Basic Science / Preclinical (33%), Case Report / Case Series (24%), and Review / Meta-Analysis (24%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 46 | 33% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:31 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about X-linked intellectual disability-seizures-psoriasis syndrome
Patient case studies |
34 |
24% |
Research summaries | 33 | 24% |
Disease patterns and progression | 11 | 8% |
New treatment approaches | 9 | 6% |
Testing and diagnosis research | 4 | 3% |
Clinical study results | 3 | 2% |
Miller JS (2026). [PMID: 41260060](https://pubmed.ncbi.nlm.nih.gov/41260060/). *Pediatric neurology*. [Basic Science / Preclinical]
Alexander JL (2026). [PMID: 41346295](https://pubmed.ncbi.nlm.nih.gov/41346295/). *Blood advances*. [Clinical Trial Publication]
Sidorina A (2026). [PMID: 41429203](https://pubmed.ncbi.nlm.nih.gov/41429203/). *J Lipid Res*. [Diagnostic / Biomarker]
Weissgold S (2026). [PMID: 42028919](https://pubmed.ncbi.nlm.nih.gov/42028919/). *J Intellect Disabil Res*. [Review / Meta-Analysis]
Bruschi F (2026). [PMID: 41144879](https://pubmed.ncbi.nlm.nih.gov/41144879/). *Mov Disord*. [Case Report / Case Series]
Pena-Ortiz MA (2026). [PMID: 41239822](https://pubmed.ncbi.nlm.nih.gov/41239822/). *Glia*. [Case Report / Case Series]
Huang R (2026). [PMID: 41205496](https://pubmed.ncbi.nlm.nih.gov/41205496/). *European journal of obstetrics, gynecology, and reproductive biology*. [Case Report / Case Series]
Jost C (2026). [PMID: 41606215](https://pubmed.ncbi.nlm.nih.gov/41606215/). *Eur J Hum Genet*. [Basic Science / Preclinical]
Boelaert K (2026). [PMID: 41508830](https://pubmed.ncbi.nlm.nih.gov/41508830/). *J Clin Endocrinol Metab*. [Review / Meta-Analysis]
Brott JT (2026). [PMID: 42048321](https://pubmed.ncbi.nlm.nih.gov/42048321/). *PLoS One*. [Basic Science / Preclinical]